

Financial Tear Sheet


Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

Stock Performance

AMGN (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	\$178.24
Change (%)	▲ 0.28 (0.16%)
Volume	1,811,957
52 Week Low	\$153.56
Market Cap	\$118,707,840,000
Rolling EPS	3.15
PE Ratio	56.5841
Shares Outstanding	666,000,000



Data as of 05/25/18 4:00 p.m. ET

Recent Headlines

05/23/18

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment

05/22/18

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

05/21/18


FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis

Upcoming Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: **2.3**



Unable to fulfill request.

SEC Filings

FILING DATE	FORM
05/22/18	3
05/22/18	8-K
05/17/18	CT ORDER
05/15/18	4

Financial Reports

Q4 2017 Financial Results

Presentations

05/21/18 Amgen Investor Insights Newsletter
Q1 2018

Data provided by Nasdaq. Minimum 15 minutes delayed.